PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC
Status:
Not yet recruiting
Trial end date:
2031-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare PD-1 inhibitor combined with preoperative
chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by
surgery, in terms of the overall survival time (OS) in patients with Stage T1-4aN1-3M0 or
T3-4aN0M0 squamous cell esophageal carcinoma.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Affiliated Cancer Hospital of Shantou University Medical College